Acrivon Therapeutics, Inc. (ACRV) AI Stock Analysis

• Market Cap: $42.33M
• Dividend Yield: N/A
• Average Volume (3M): 369.06K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.48
• Revenue Growth: N/A
• EPS Growth: 10.84%
• Country: US
• Employees: 75
• Sector: Healthcare
• Sector Strength: 40
• Industry: Biotechnology
• EPS (TTM): -0.51
• Shares Outstanding: 31,355,362
• 10 Day Avg. Volume: 248,932
• 30 Day Avg. Volume: 369,063
• PEG Ratio: -0.05
• Price to Book (P/B): 0.30
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.57
• Enterprise Value/Market Cap: 0.11
• Enterprise Value/Revenue: 1.19
• Enterprise Value/Gross Profit: -22.47
• Enterprise Value/Ebitda: -0.01
• 1Y Price Target: $10.25
• Price Target Upside: 632.14% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 7

• Rating: 36 Underperform
• Price Target: ―

Acrivon Therapeutics, Inc. faces major financial challenges, including no revenue, increasing losses, and negative cash flows, leading to a low overall score. The weak technical indicators further compound these concerns. However, recent corporate events, such as advancements in clinical programs and an extended cash runway, offer some optimism for future prospects. Investors should be cautious due to the company's current financial instability.

Positive Factors

Clinical Trials

Acrivon reported promising interim Phase 2b data for ACR-368, showing a confirmed overall response rate of 35% and a disease control rate of 80% in OncoSignature-positive patients.

Pipeline Development

Acrivon is continuing to build its pipeline, with a novel first-in-class cell cycle drug expected to be nominated for development within 2025.

Safety Profile

The safety profile of ACR-368 is consistent with prior data, with no long-lasting myelosuppression or liver toxicities, supporting its efficacy in endometrial cancer.

Negative Factors

Efficacy Concerns

The stock has experienced pressure following the company's R&D day due to the lower than expected efficacy of ACR-368 in endometrial cancer compared to previous updates and competitor drugs.

Market Competition

Acrivon announced that it will deprioritize development in ovarian and bladder cancer due to the evolving competitive landscape in both indications.

Product Launch Delays

The launch in endometrial cancer has been pushed back to 2028, reducing the technology value and peak sales estimates.

Acrivon Therapeutics, Inc. Business Overview & Revenue Model

Company Description

Acrivon Therapeutics, Inc. (ACRV) is a clinical-stage biopharmaceutical company focused on developing targeted oncology therapies. The company leverages its proprietary precision medicine platform to identify patients most likely to benefit from its drug candidates. Acrivon's core products include advanced drug candidates designed to address specific unmet needs in cancer treatment.

How the Company Makes Money

Acrivon Therapeutics, Inc. makes money primarily through the development and commercialization of its targeted oncology therapies. The company generates revenue by advancing its drug candidates through clinical trials with the aim of obtaining regulatory approval and subsequently marketing these therapies. Key revenue streams include potential licensing agreements, partnerships with other pharmaceutical companies, and milestone payments upon achieving specific clinical and regulatory milestones. Additionally, Acrivon may engage in collaborative research and development agreements to enhance its pipeline and broaden its market reach.

Acrivon Therapeutics, Inc. Financial Statement Overview

Summary

Acrivon Therapeutics, Inc. faces significant financial challenges with no revenue generation and increasing net losses. While the balance sheet shows a strong equity position, the cash flow is concerning due to heavy reliance on external financing. Overall, the financial health of the company needs improvement to ensure long-term viability.

Income Statement

The company has not generated any revenue over the analyzed period, which is a significant concern. Net income has consistently been negative, and losses have widened over time, with EBIT and EBITDA showing a similar trend. The lack of revenue and increasing losses place the company in a challenging financial position.

Balance Sheet

The company maintains a strong equity position relative to its liabilities, with a high equity ratio. However, the total debt has been managed at a low level, which is a positive sign. Despite these strengths, the consistent net losses reduce the overall value of the equity position.

Cash Flow

Operating cash flow has been consistently negative, indicating that the company is not generating enough cash to cover its operating expenses. Free cash flow is also negative, and the company relies heavily on financing activities to offset cash deficits. This reliance poses potential long-term sustainability risks.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	-536.00K	-1.09M	-832.00K	-13.00K
EBITDA	-79.55M	-59.85M	-30.07M	-15.41M	-5.29M
Net Income	-80.56M	-60.39M	-29.68M	-16.24M	-5.31M
Balance Sheet
Total Assets	196.59M	138.26M	181.23M	106.59M	2.19M
Cash, Cash Equivalents and Short-Term Investments	179.48M	127.46M	127.75M	99.60M	1.58M
Total Debt	3.65M	4.64M	4.96M	5.63M	58.00K
Total Liabilities	19.80M	17.07M	10.75M	130.40M	10.60M
Stockholders Equity	176.79M	121.19M	170.47M	-23.81M	-8.41M
Cash Flow
Free Cash Flow	-68.44M	-43.93M	-32.28M	-14.22M	-2.82M
Operating Cash Flow	-65.67M	-42.64M	-30.12M	-13.98M	-2.80M
Investing Cash Flow	-51.77M	50.72M	-141.68M	-238.00K	-15.00K
Financing Cash Flow	121.03M	-1.55M	101.71M	112.22M	2.89M

Acrivon Therapeutics, Inc. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1.40
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ACRV, the sentiment is Neutral. The current price of 1.4 is above the 20-day moving average (MA) of 1.29, above the 50-day MA of 1.23, and below the 200-day MA of 4.46, indicating a neutral trend. The MACD of 0.02 indicates Negative momentum. The RSI at 59.72 is Neutral, neither overbought nor oversold. The STOCH value of 71.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ACRV.

Acrivon Therapeutics, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AVTX	54 Neutral	$67.67M	―	678.24%	―	-69.59%	―
Sector *	52 Neutral	$7.37B	-0.04	-63.81%	2.59%	16.40%	<0.01%
BLUE	51 Neutral	$48.67M	―	-546.55%	―	127.51%	56.94%
GUTS	47 Neutral	$87.67M	―	-196.81%	―	―	―
STRO	39 Underperform	$64.19M	―	-679.15%	―	-56.88%	-57.57%
CYCC	38 Underperform	$20.70M	―	-1949.77%	―	-89.76%	80.28%
ACRV	36 Underperform	$42.33M	―	-62.41%	―	―	10.84%

Acrivon Therapeutics, Inc. Corporate Events

Acrivon Therapeutics Appoints New Chief Medical Officer

On April 7, 2025, Acrivon Therapeutics announced the appointment of Mansoor Raza Mirza, M.D., as Chief Medical Officer, effective April 9, 2025. Dr. Mirza, a distinguished oncologist with a robust background in gynecologic oncology, will lead clinical development efforts, including the ongoing ACR-368 Phase 2b trial in endometrial cancer and the ACR-2316 Phase 1 study. His appointment is expected to strengthen Acrivon’s clinical leadership and advance the company’s pipeline towards regulatory submissions and potential approvals, enhancing its position in the precision oncology field.

Spark’s Take on ACRV Stock

According to Spark, TipRanks’ AI Analyst, ACRV is a Underperform.

Acrivon’s overall stock score is low due to significant financial challenges, including no revenue, increasing losses, and negative cash flows. The weak technical indicators further compound these concerns. However, recent corporate events showing progress in clinical programs and an extended cash runway offer some optimism for future prospects.

To see Spark’s full report on ACRV stock, click here.

Acrivon Therapeutics Reports 2024 Financial Results and Progress

On March 27, 2025, Acrivon Therapeutics announced its financial results for the fourth quarter and full year 2024, highlighting significant progress in its clinical programs. The company reported promising data from its ACR-368 trials for endometrial cancer, showing a high response rate in heavily pretreated patients, and prioritized this cancer type due to limited treatment options and commercial potential. Additionally, the Phase 1 trial of ACR-2316 is ahead of schedule, with early signs of clinical activity. Acrivon has extended its cash runway into 2027, allowing continued focus on its AP3 platform and drug development efforts.

Acrivon Therapeutics Appoints New Chief Financial Officer

On March 14, 2025, Acrivon Therapeutics announced the appointment of Adam Levy, Ph.D., M.B.A., as Chief Financial Officer effective April 1, 2025. Dr. Levy brings over 25 years of experience in finance and investor relations within the biopharma sector, having previously held senior roles at companies like Zentalis Pharmaceuticals and Gilead Sciences. His appointment follows the departure of Rasmus Holm-Jorgensen, who is stepping down for personal reasons to pursue an opportunity in Europe. This leadership change is not due to any disagreements within the company, and it is expected to strengthen Acrivon’s financial strategy and investor relations.